XERS 240816 2.50C (XERS240816C2500) Stock Options, News & Quotes

0.15
+0.02+15.38%

15min DelayClose Aug 2 15:59 ET

0.20High0.15Low

SymbolStock Name

Latest PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Trytosaveabit

Jul 8 06:14

Hmm

$Xeris Pharmaceuticals(XERS.US)$ Xeris Biopharma Reports Preliminary Q2 Total Revenue To Exceed $47M, Representing Over 23% Growth Over Last Year; Estimate $44.894M

Trytosaveabit

May 30 13:16

$Xeris Pharmaceuticals(XERS.US)$ And you were doing so lovely! Oh well still a nice PI on fairly benign PR as far as a catalyst for moving up

Trytosaveabit

May 30 06:35

Update

$Xeris Pharmaceuticals(XERS.US)$ Xeris Biopharma Holdings Inc - FDA End-of-Phase 2 Interaction to Facilitate a Phase 3 Pivotal Study Program Is Expected by Year-End

Jaguar8

May 30 06:31

NEWS

$Xeris Pharmaceuticals(XERS.US)$
Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol™-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121)
Xeris Biopharma announced positive topline results from its Phase 2 study of XP-8121, a once-weekly subcutaneous levothyroxine (SC) formulation. The study showed that XP-8121 provides predictable bioavailability and sustained levothyroxine levels, achieving normalized TSH/T4 levels with 45% less drug...

Trytosaveabit

May 6 06:03

Update

$Xeris Pharmaceuticals(XERS.US)$ Reuters· 1 min ago
Xeris Biopharma: Potential to Get Development Payments, Plus Low Double-Digit Royalties Based on Future Sales of Xeris Glucagon for Pumps, Pump Systems